Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.63 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | PI4KA | P42356 | 3/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.35 |
| ▸ | XDH | P47989 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.35 |
| ▸ | PRKDC | P78527 | 4/20 | 0.35 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14736182 | 0.85 | CHEK1 (0.51) | CHEK1TRPA1RETMAPK1PI4KA | |
| SCHEMBL22912722 | 0.81 | CHEK1 (0.66) | CHEK1TRPA1MAPK1LRRK2DYRK3 | |
| SCHEMBL5805420 | 0.78 | RET (0.43) | CHEK1RETPI4KAPI4K2BPI4K2A | |
| SCHEMBL61206 | 0.78 | CHEK1 (1.00) | CHEK1TRPA1MAPK1LRRK2DYRK1A | |
| SCHEMBL7887899 | 0.78 | CHEK1 (0.61) | CHEK1TRPA1MAPK1LRRK2DYRK3 | |
| SCHEMBL2537071 | 0.78 | CHEK1 (0.61) | CHEK1TRPA1MAPK1LRRK2PRKD3 | |
| SCHEMBL30052782 | 0.77 | RET (0.42) | CHEK1TRPA1RETPI4KAPI4K2B | |
| SCHEMBL6531144 | 0.77 | RET (0.42) | CHEK1TRPA1RETPI4KAPI4K2B | |
| SCHEMBL23735452 | 0.75 | CHEK1 (0.48) | CHEK1TRPA1RETPI4KAPI4K2B | |
| SCHEMBL10259826 | 0.75 | AKT1 (0.45) | CHEK1TRPA1RETPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577249-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4317162-B1 | 1,3-BENZODIOXOLANE-CONTAINING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | XIAN XINTONG PHARMACEUTICAL RES CO LTD (CN) | 2026-02-04 | — | — | EP | disclosed |
| EP-4306529-B1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12522605-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20250154154-A1 | SRC INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| EP-4553077-A1 | SULFOXIMINE COMPOUND HAVING FGFR INHIBITORY EFFECT, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Kinoteck Therapeutics Co., Ltd (CN) | 2025-05-14 | — | — | EP | disclosed |
| CN-119874707-A | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-4524154-A2 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2025-03-19 | — | — | EP | disclosed |
| EP-3848054-B1 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2025-01-29 | — | — | EP | disclosed |
| EP-2305682-A1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| US-7820662-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-2168968-A1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20100009963-A1 | KINASE ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090325928-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7585868-B2 | Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-09-08 | — | — | US | disclosed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-20 | — | — | US | disclosed |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | MTOR, PI4KA, PIK3CA | CHEK1 434/4885TRPA1 4171/4885RET 295/4885 |
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | STING1, CGAS, CDA | CHEK1 819/4885TRPA1 3270/4885RET 2275/4885 |
| US-20090325928-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | CHEK1 188/4885TRPA1 2776/4885RET 686/4885 |
| US-12577249-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | CHEK1 364/4885TRPA1 4124/4885RET 971/4885 |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | CHEK1 188/4885TRPA1 2776/4885RET 686/4885 |
| US-20100009963-A1 | KINASE ANTAGONISTS | MTOR, RPS6KA3, AKT3 | CHEK1 352/4885TRPA1 4219/4885RET 289/4885 |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | IGF1R, MAP2K7, BRCA1 | CHEK1 188/4885TRPA1 2776/4885RET 686/4885 |
| US-20250154154-A1 | SRC INHIBITORS AND USES THEREOF | SRC, LCK, FYN | CHEK1 677/4885TRPA1 3985/4885RET 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.